Large Study Finds No Lung Cancer Risk from GLP-1 Drugs or DPP-4 Inhibitors in Diabetic Patients | Research

The takeaway

A study of over 130,000 type 2 diabetes patients found no association between incretin-based drugs (GLP-1 agonists and DPP-4 inhibitors) and lung cancer risk over a median 4.6-year follow-up.

No increased risk (HR ~1.0)
Neither GLP-1 agonists nor DPP-4 inhibitors increased lung cancer risk in 130,340 diabetic patients

What the researchers found

Neither DPP-4 inhibitors (HR 1.07, 95% CI 0.87-1.32) nor GLP-1 receptor agonists (HR 1.02, 95% CI 0.68-1.54) were associated with increased lung cancer risk, with no duration-response relationship.

Why it matters

Safety concerns about cancer risk from newer diabetes medications need rigorous evaluation. This large study provides reassurance that incretin-based drugs do not increase lung cancer risk.

The numbers in context

130,340 patients; 790 lung cancers; median 4.6 yr follow-up; DPP-4i HR 1.07 (0.87-1.32); GLP-1 RA HR 1.02 (0.68-1.54)

How the study worked

Population-based cohort study using UK CPRD. 130,340 individuals newly treated with antidiabetes drugs (2007-2017), followed until 2018. Time-varying Cox proportional hazards models comparing incretin drugs to other second/third-line diabetes drugs. Assessed cumulative duration and time since initiation.

Who was studied

Newly treated type 2 diabetes patients in the UK (2007-2017)

What this study cannot tell us

Observational — cannot prove causation. Median 4.6-year follow-up may be insufficient for cancers with long latency. Residual confounding possible. GLP-1 agonist subgroup relatively small (wide confidence intervals).

How to read the evidence

Strong — large population-based cohort study with validated outcome data, appropriate statistical methods, and sufficient power for the primary analysis.

When this study was published

Published in 2020; GLP-1 drug safety data continues to accumulate with expanding use in obesity and diabetes.

The bigger picture

As GLP-1 drugs expand beyond diabetes into obesity treatment, cancer safety data becomes increasingly important. This study adds to the reassuring evidence base for long-term incretin-based therapy safety.

Questions still open

Would longer follow-up (10+ years) reveal any late-emerging cancer signal?
Do specific GLP-1 receptor agonists differ in cancer risk profiles?
Does the protective anti-inflammatory effect of GLP-1 drugs provide any cancer risk reduction?

Common questions

Why were researchers concerned about lung cancer with these diabetes drugs?

GLP-1 receptors are expressed in lung tissue, and some preclinical studies raised theoretical concerns about incretin signaling promoting cell growth. This large study was designed to test whether this theoretical risk translated into actual cancer cases.

Does this mean GLP-1 drugs are completely safe regarding cancer?

This study is reassuring for lung cancer specifically, but 4.6 years of follow-up may not capture very long-latency effects. Ongoing pharmacovigilance is important, especially as these drugs are used by millions of patients.

Read the original research

Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes.

Diabetic medicine : a journal of the British Diabetic Association, 37(5), 868-875

View on PubMed ↗Publisher’s paper ↗

Citation

Rouette, J; Yin, H; Yu, O H Y; Bouganim, N; Platt, R W; Azoulay, L. (2020). Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes.. Diabetic medicine : a journal of the British Diabetic Association, 37(5), 868-875. https://doi.org/10.1111/dme.14287